All In MedTech

FDA Clearance Tracker · P190016

Tula® System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Nov 25, 2019 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product codeBreakthrough

Decided

Nov 25, 2019

Approved

Time to decision

178 days

Received May 31, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P190016
Device name
Tula® System
Applicant location
Menlo Park, CA
Received
May 31, 2019
Decided
Nov 25, 2019
Decision
Approved
Supplements
11 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code QJA

FDA's approval statement

As written in FDA's record.

Approval for the Tula® System. This device is intended to create a myringotomy and insert a tympanostomy tube using the Tula Tube Delivery System in pediatric (aged 6 months and older) and adult patients indicated to receive tympanostomy tubes. The Tula System is used to deliver a tympanostomy tube under local anesthesia induced using the Tula Iontophoresis System and TYMBION, a combination of an amide local anesthetic and an alpha- and beta-adrenergic agonist.TYMBION, a combination of an amide local anesthetic and an alpha- and beta-adrenergic agonist, is indicated for the induction of local anesthesia of the tympanic membrane via iontophoresis using the Tula® Iontophoresis System in pediatric (aged 6 months and older) and adult patients undergoing tympanostomy tube placement using the Tula Tube Delivery SystemDrug Indications and Usage: TYMBION, a combination of an amide local anesthetic and an alpha- and beta-adrenergic agonist, is indicated for the induction of local anesthesia of the tympanic membrane via iontophoresis using the Tula® Iontophoresis System in pediatric (aged 6 months and older) and adult patients undergoing tympanostomy tube placement using the Tula Tube Delivery System.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code QJA (Tympanostomy tube delivery product with drug).
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for Tusker Medical, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.